Pfizer Inc. (PFE) and Astellas Announce Phase 3 ARCHES Trial Shows XTANDI Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer

February 11, 2019 5:01 PM
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. announced today results from the Phase 3 ARCHES trial in men with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot FDA News

Next Articles